Table 2.
The risks of atrophy gastritis in groups of different subjects.
| Covariate | Healthy controls | Symptomatic cancer-free | Gastric cancer | |||
|---|---|---|---|---|---|---|
| CAG prevalence | aOR (95% CI) | CAG prevalence | aOR (95% CI) | CAG prevalence | aOR (95% CI) | |
| Sex | ||||||
| Female | 17.1‰ | ref. | 38.1‰ | ref. | 72.2‰ | ref. |
| Male | 14.9‰ | 1.00 (0.68–1.49) | 16.4‰ | 0.44 (0.14–1.33) | 48.1‰ | 0.71 (0.25–2.05) |
| Age (yrs) | ||||||
| <40 | 5.0‰ | ref. | 0‰ | — | 0‰ | — |
| 40–59 | 14.5‰ | 1.82 (0.93–3.58) | 32.3‰ | ref. | 66.1‰ | ref. |
| 60– | 43.2‰ | 3.01 (1.46–6.21) | 37.0‰ | 1.20 (0.42–3.44) | 57.3‰ | 1.43 (0.50–4.10) |
| Serum G-17 | ||||||
| Normal | 1.9‰ | ref. | 7.9‰ | ref. | 37.4‰ | ref. |
| Low | 1.7‰ | 0.96 (0.33–2.76) | 6.2‰ | 0.87 (0.09–8.53) | 0‰ | — |
| High | 38.9‰ | 20.67 (9.17–46.55) | 13.7‰ | 1.97 (0.20–19.31) | 61.2‰ | 1.71 (0.42–6.98) |
| Very high | 400.7‰ | 314.41 (166.10–595.12) | 250.0‰ | 42.40 (11.63–154.66) | 170.7‰ | 5.50 (1.78–17.02) |
Abbreviations: aOR, adjusted odds ratio; CAG, chronic atrophic gastritis; CI, confidence interval; G-17, gastrin-17; ref., reference.